Nowadays, functionalized nanoparticles are opening a wide range of opportunities to improve the diagnosis and treatment of different kind of pathologies.
A research group from a major Spanish university has developed and patented functionalized nanoparticles that are focussed in the integration of diagnosis and therapy in one nanodevice, so called theragnosis. This approach enables the diagnosis together with the treatment and monitoring of the treatment efficiency and disease progress at the same time.
The nanoparticles are conjugated with the following agents:
• A tumour-specific ligand refers to any molecule, particularly any peptide, which is tumour-specific of the tumour to be treated or diagnosed. This ligand is conjugated to the surface of the nanoparticle.
• An imaging tracker refers to any agent that can be used for monitoring the efficacy of the treatment or the diagnosis.
• Drug/s to treat the tumour
Unlike nanoparticles for theragnostic known in the prior art, where the drug and the imaging tracker are heterogeneously encapsulated inside the particle, the controlled multi-functionalization of these new nanoparticles allows tuning the ratio between the amounts of each one of the components: the drug, the ligand and the diagnostic agent. This fact increases dramatically the possibilities of developing more effective nanodevices for controlled released and monitoring in real time.
The university is looking for a pharmaceutical company in order to reach a license agreement for the patented technology.